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Summary 
A phase II trial of combination chemotherapy with mitoxantrone, cisplatin, and methyl-glyoxal bix-guanyl- 
hydrazone (MGBG) was conducted in 32 patients with unfavorable histology malignant lymphoma. All pa- 
tients had relapsed after only one prior chemotherapy regimen (CHOP - 56%; mBACOD - 28%). There 
were three complete and eight partial responses (overall response rate - 34%) among 32 eligible patients. 
The median duration of remission was 6.0 months. Severe granulocytopenia was common, with 19/32 pa- 
tients (63%) suffering life-threatening, and 1/32 (3%) suffering fatal, granulocytopenia. 
We conclude that mitoxantrone-cisplatin-MGBG has modest activity as salvage treatment in malignant 
lymphoma patients, but produces severe toxicity. 
Introduction 
Although increasingly intensive chemotherapy pro- 
grams for patients with unfavorable histology 
malignant lymphomas are producing increasingly 
higher complete remission and long-term disease 
free survival rates [1-3], a significant number of 
patients fail induction therapy or relapse after com- 
plete remission. 
Retreating these patients with front-line regimens 
rarely produces complete remissions or alters the 
clinical course [4,5], so attention has focused on the 
use of standard drugs in newly designed combina- 
tions and on investigational drugs as salvage thera- 
py. Single agents such as etoposide, cisplatin, 
mitoxantrone, m-AMSA, cytosine arabinoside, 
MGBG, VM-26, and the nitrosoureas have activity 
in lymphoma salvage. In various combinations, 
these drugs produce response rates of 30-40% 
[6-10]. Unfortunately, the responses are usually 
partial and brief. 
The Southwest Oncology Group conducted a pi- 
lot study of cisplatin, MGBG and m-AMSA in pa- 
tients with refractory unfavorable histology lym- 
phomas [11]. A partial response rate of 43% was 
seen in 30 patients but the median response dura- 
tion was only two months. Severe leukopenia, in- 
cluding one fatality, was the principal side effect. 
In the present study, we substituted mitoxan- 
trone for m-AMSA because of pre-clinical and 
phase II data suggesting good antilymphoma activi- 
ty for this new anthracene analogue [12,13], and 
synergism between mitoxantrone and cisplatin in 
animal tumor models [14]. Since the dose limiting 
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Table 1. Characteristics and responses of 32 lymphoma patients 
receiving cisplatin, MGBG, and mitoxantrone 
N 
Median age (range) 62 yr (18-92) 
Sex 
Male 19 (59%) 
Female 13 (41%) 
Performance status 
0 16 (5007o) 
1 16 (50~ 
Risk assessment 
Good 10 (31%) 
Poor 22 (69%) 
Prior therapy 
CHOP 18 (56%) 
mBACOD 9 (28%) 
other 5 (15%) 
Histology a 
DHL 19 (59070) 
DUL 3 (907o) 
DML 3 (9070) 
DLPD 7 (2207o) 
Responses 
CR 3 (907o) 
PR 8 (2507o) 
NR 21 (6507o) 
a DUL = diffuse undifferentiated lymphoma; DHL = diffuse 
histiocytic lymphoma; DML = diffuse mixed lymphocytic- 
histiocytic lymphoma; DLPD = diffuse poorly differentiated 
lymphocytic lymphoma. 
toxicity of  mitoxantrone is the same as that of m- 
AMSA, namely granulocytopenia, and since cispla- 
tin and MGBG have a spectrum of non-overlapping 
toxicities we anticipated that the combination of 
cisplatin, MGBG, and mitoxantrone would be as 
safely tolerated as the combination given in our 
earlier study [111. 
Patients  and methods  
Eligibility requirements to enter this study included 
a diagnosis of  unfavorable histology malignant 
lymphoma refractory to no more than one prior 
chemotherapy regimen; measurable disease; per- 
formance status of  0, 1, or 2 (ECOG criteria); abso- 
lute granulocyte count >2000//d;  platelet count 
> 100,000/~1; BUN < 20 mg/dl  and serum creati- 
nine < 1.7 mg/dl ;  fasting blood sugar > 60 mg/dl ;  
and a prior doxorubicin dose <450 m g / m  2. Pa- 
tients were considered poor risk if they were > 65 
years of  age, had known marrow involvement, had 
extensive prior irradiation to hematopoietic bone 
marrow, or had unexpectedly severe myelosuppres- 
sion with prior chemotherapy. 
The treatment program included mitoxantrone 
12 m g / m  ~ IV, MGBG 500 m g / m  2 IV, and cisplatin 
50 m g / m  2 IV, all given on day 1 and repeated at 
21-day intervals. Poor  risk patients received the 
same doses of  MGBG and cisplatin but mitoxan- 
trone was reduced to 10 m g / m  ~ IV. Doses of  mitox- 
antrone and MGBG were escalated or reduced to 
achieve a granulocyte nadir count of  1000-1999//A 
or a platelet nadir count of  75,000-99,999/tA. 
An adequate trial of  treatment required that two 
courses be given. Treatments were continued until 
tumor progression. 
Standard response criteria were used [15]. 
Results 
Thirty-five patients were registered on this study 
between August 1984 and July 1986. Three had 
favorable histology lymphoma on pathology review 
and were ineligible. Seven patients received only 
one course of  treatment which was considered an 
inadequate trial. These patients are included in the 
analysis and assumed to have no response. 
Patient characteristics and responses are present- 
ed in Table 1. Among thirty-two eligible patients, 
three achieved a complete remission (CR) and eight 
achieved a partial remission (PR), for an overall 
response rate of  34%. The median overall survival 
from date of  first treatment for all eligible patients 
was 6.4 months. 
The characteristics of  responding patients are 
presented in Table 2. The median duration of com- 
plete responses was 4 months,  and the median dura- 
tion of  partial responses was 7 months.  Two of 
three complete responders had diffuse undifferen- 
tiated lymphoma,  while 6 of  8 partial responders 
had diffuse poorly differentiated lymphocytic 
lymphoma.  
Toxicity was severe. Fatal granulocytopenia oc- 
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Table 2. Characteristics of responding patients 
Prior Risk Response Histology 
therapy a assessment duration (mo) 
Complete CHOP poor 6 DUL 
responders CHOP poor 4 DHL 
m-BACOD poor 3 DUL 
Partial 
responders 
CHOP-bleomycin good 12 DML 
CHOP poor 10 DLPD 
CHOP poor 9 DLPD 
CHOP poor 7 DLPD 
CHOP poor 7 DLPD 
COP-BLAM good 3 DHL 
m-BACOD poor 1 DLPD 
CHOP-araC poor 4 DLPD 
a CHOP = cyclophosphamide, doxorubicin, vincristine, prednisone; m-BACOD = methotrexate, bleomycin, cyclophosphamide, dox- 
orubicin, vincristine, dexamethasone; COP-BLAM = cyclophosphamide, doxorubicin, vincristine, prednisone, bleomycin, procar- 
bazine. 
curred in one poor-risk patient, and 19 patients had 
life-threatening granulocytopenia (63%). Moder- 
ate-to-severe toxicities included nausea/vomiting 
(56%), thrombocytopenia (31%), anemia (25%), 
diarrhea (6%), and mucositis (9%). Renal toxicity 
was not seen. 
Discussion 
In this trial, combination chemotherapy with 
cisplatin, MGBG and mitoxantrone produced an 
overall response rate (34%) comparable to that 
achieved by a variety of lymphoma salvage regi- 
mens, including others based on cisplatin and pro- 
grams incorporating etoposide or cytosine arabino- 
side. The median duration of  responses obtained 
(6.0 months) is likewise comparable to that seen in 
a recent report of  a similar MGBG-based lympho- 
ma salvage treatment [16]. It is interesting to note 
that 9/22 patients receiving attenuated mitoxan- 
trone doses because of anticipated poor marrow 
reserve responded to therapy, while only 2/10 pa- 
tients receiving full dose therapy responded. This 
difference is not statistically significant, but sug- 
gests that mitoxantrone contributed little to the an- 
titumor activity of  this regimen. 
Responses were seen most frequently in the 
diffuse undifferentiated (2/3) and diffuse poorly 
differentiated lymphocytic (6/7) subtypes of un- 
favorable lymphomas in our study. In contrast, 
only 1/19 patients with diffuse histiocytic and 1/3 
patients with diffuse mixed lymphoma responded. 
Our results support further study of  cisplatinum 
and MGBG combinations as salvage therapy for 
malignant lymphoma, particularly the diffuse 
poorly differentiated lymphocytic subtype. 
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